Alvogen agrees biosimilar commercial deals in three major markets

By Staff Reporter

- Last updated on GMT

(Image: Getty/Metamorworks)
(Image: Getty/Metamorworks)

Related tags: Alvogen, Alvotech, Forteo, Eli lilly, Pfenex

Biosimilar developer agrees three different distribution partners in South Korea, Israel and Canada for biosimilar to Forteo.

Alvogen has signed agreements with PharmBio, Kamada and Jamp, for each country, respectively. The company’s biosimilar, PF708, is still subject to approval in the three countries.

The biosimilar was originally developed by Pfenex, but the two companies entered into a development and commercialization agreement​ that would see Alvogen take the lead in certain European countries, the Middle East, North Africa and the ‘rest of world’ territories.

Earlier this month​, PF708 was approved in the US and is known by the brand name, Bonsity. The biosimilar is also currently going through the regulatory process with the European Medicines Agency.

Forteo (teriparatide) is Eli Lilly’s treatment for men and postmenopausal women with osteoporosis. The treatment managed global sales of $1.6bn (€1.4bn) in 2018.

In addition to securing partners in the three countries, Alvogen also noted that it had submitted for marketing authorization in Saudi Arabia.

Alvogen will manufacture the biosimilar out of its subsidiary’s $250m Iceland-based manufacturing plant​.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us


View more